BioMarin Pharmaceuticals BMRN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's operating cash flow?
- BioMarin Pharmaceuticals (BMRN) reported operating cash flow of $220.65M in Q1 2026.
- How has BioMarin Pharmaceuticals's operating cash flow changed year-over-year?
- BioMarin Pharmaceuticals's operating cash flow increased by 26.5% year-over-year, from $174.39M to $220.65M.
- What is the long-term trend for BioMarin Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's operating cash flow has grown at a 28.4% compound annual growth rate (CAGR), from $304.54M to $827.99M.
- What does operating cash flow mean?
- The actual cash generated by the company's day-to-day business.
- How do you interpret operating cash flow?
- Higher values indicate strong operational health and the ability to self-fund; negative values may signal a need for external financing.
- How does operating cash flow compare across companies?
- The most fundamental metric for comparing operational performance across all public companies.